Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity

Weiner, 1983, Mechanism of cisplatin nephrotoxicity, Fed. Proc., 42, 2974 Kuhlmann, 1997, Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application, Nephrol. Dial. Transplant., 12, 2478, 10.1093/ndt/12.12.2478 Babu, 1995, Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester, Mol. Cell. Biochem., 144, 7, 10.1007/BF00926734 Matsushima, 1998, The role of oxygen free radicals in cisplatin-induced acute renal failure in rats, J. Lab. Clin. Med., 131, 518, 10.1016/S0022-2143(98)90060-9 Sueishi, 2002, Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats, Eur. J. Pharmacol., 451, 203, 10.1016/S0014-2999(02)02251-3 Kruidering, 1997, Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain, J. Pharmacol. Exp. Ther., 280, 638 Kim, 1997, Effects of antioxidants and Ca2+ in cisplatin-induced cell injury in rabbit renal cortical slices, Toxicol. Appl. Pharmacol., 146, 261, 10.1006/taap.1997.8252 Schaaf, 2002, Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells, Free Radic. Res., 36, 835, 10.1080/1071576021000005267 Lieberthal, 1996, Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis, Am. J. Physiol., 270, F700 Lau, 1999, Apoptosis induced by cisplatin nephrotoxic injury, Kidney Int., 56, 1295, 10.1046/j.1523-1755.1999.00687.x Cummings, 2002, Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways, J. Pharmacol. Exp. Ther., 302, 8, 10.1124/jpet.302.1.8 Park, 2002, Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways, J. Am. Soc. Nephrol., 13, 858, 10.1681/ASN.V134858 Shino, 2003, Role of poly(ADP-ribose) polymerase in cisplatin-induced injury in LLC-PK1 cells, Free Radic. Biol. Med., 35, 966, 10.1016/S0891-5849(03)00470-2 Ramesh, 2002, TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity, J. Clin. Invest., 110, 835, 10.1172/JCI200215606 Ramesh, 2003, TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure, Am. J. Physiol. Renal Physiol., 285, F610, 10.1152/ajprenal.00101.2003 Ramesh, 2005, p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice, Am. J. Physiol. Renal Physiol., 289, F166, 10.1152/ajprenal.00401.2004 Nakamura, 2001, Activation of β2-adrenoceptor prevents shiga toxin 2-induced TNF-α gene transcription, J. Am. Soc. Nephrol., 12, 2288, 10.1681/ASN.V12112288 Nakamura, 2000, β2-Adrenoceptor agonist suppresses tumour necrosis factor production in rat mesangial cells, Cytokine, 12, 491, 10.1006/cyto.1999.0581 Zhang, 1997, Increased intracellular cyclic adenosine 3′, 5′-monophosphate inhibits release of tumor necrosis factor-α from human vascular tissue and cultured smooth muscle cells, Crit. Care Med., 25, 1855, 10.1097/00003246-199711000-00025 Newman, 1998, Release of tumor necrosis factor-α from coronary smooth muscle: activation of NF-κB and inhibition by elevated cyclic AMP, J. Surg. Res., 80, 129, 10.1006/jsre.1998.5456 Chong, 2002, Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-α production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein, J. Neuroimmunol., 133, 160, 10.1016/S0165-5728(02)00349-1 Bai, 2001, The cytotoxic effects of diesel exhaust particles on human pulmonary artery endothelial cells in vitro: role of active oxygen species, Free Radic. Biol. Med., 30, 555, 10.1016/S0891-5849(00)00499-8 Kubota, 2004, Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors, Biochem. Pharmacol., 67, 2175, 10.1016/j.bcp.2004.02.037 Takahashi, 2001, Estimation of lipid peroxidation of live cells using a fluorescent probe, diphenyl-1-pyrenylphosphine, Free Radic. Biol. Med., 31, 164, 10.1016/S0891-5849(01)00575-5 Senator, 2004, Prion protein protects against DNA damage induced by paraquat in cultured cells, Free Radic. Biol. Med., 37, 1224, 10.1016/j.freeradbiomed.2004.07.006 Peskin, 2000, A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1), Clin. Chim. Acta, 293, 157, 10.1016/S0009-8981(99)00246-6 Preuss, 2000, Role of antioxidant enzyme expression in the selective cytotoxic response of glioma cells to gamma-linolenic acid supplementation, Free Radic. Biol. Med., 28, 1143, 10.1016/S0891-5849(00)00210-0 Ingram, 2000, Nitric oxide modulates mechanical strain-induced activation of p38 MAPK in mesangial cells, Am. J. Physiol. Renal Physiol., 279, F243, 10.1152/ajprenal.2000.279.2.F243 Chijiwa, 1990, J. Biol. Chem., 265, 5267, 10.1016/S0021-9258(19)34116-X Akasaka, 1987, Study on aromatic phosphines for novel fluorometry of hydroperoxides (II)—the determination of lipid hydroperoxides with diphenyl-1-pyrenylphosphine, Anal. Lett., 20, 797, 10.1080/00032718708062929 Akasaka, 1992, High-performance liquid chromatography and postcolumn derivatization with diphenyl-1-pyrenylphosphine for fluorometric determination of triacylglycerol hydroperoxides, J. Chromatogr., 596, 197, 10.1016/0021-9673(92)85007-G Nicolai, 1996, Cyclic AMP-induced differentiation increases the synthesis of extracellular superoxide dismutase in rat C6 glioma, Free Radic. Biol. Med., 21, 481, 10.1016/0891-5849(96)00122-0 Adachi, 1999, Increase of urinary extracellular-superoxide dismutase level correlated with cyclic adenosine monophosphate, FEBS Lett., 458, 370, 10.1016/S0014-5793(99)01185-0 Yoshimoto, 2004, Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells, Endocrinology, 145, 3331, 10.1210/en.2003-1583 Wong, 1989, Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor, Cell, 58, 923, 10.1016/0092-8674(89)90944-6 Yamakawa, 1999, Intracellular signaling in rat cultured vascular smooth muscle cells: roles of nuclear factor-κB and p38 mitogen-activated protein kinase on tumor necrosis factor-α production, Endocrinology, 140, 3562, 10.1210/endo.140.8.6914 Nick, 2002, Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase, J. Immunol., 169, 5260, 10.4049/jimmunol.169.9.5260 Nick, 1999, Selective activation and functional significance of p38(mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils, J. Clin. Invest., 103, 851, 10.1172/JCI5257 Chong, 2002, Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-α production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein, J. Neuroimmunol., 133, 160, 10.1016/S0165-5728(02)00349-1 Yoon, 2003, α-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-α production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor κB signaling pathways, J. Biol. Chem., 278, 32914, 10.1074/jbc.M302444200 Won, 2004, Dual role of cAMP in iNOS expression in glial cells and macrophages is mediated by differential regulation of p38-MAPK/ATF-2 activation and iNOS stability, Free Radic. Biol. Med., 37, 1834, 10.1016/j.freeradbiomed.2004.08.017 Feng, 2002, cAMP elevators inhibit LPS-induced IL-12 p40 expression by interfering with phosphorylation of p38 MAPK in murine peritoneal macrophages, Cell Res., 12, 331, 10.1038/sj.cr.7290135 Rahman, 2004, cAMP targeting of p38 MAP kinase inhibits thrombin-induced NF-κB activation and ICAM-1 expression in endothelial cells, Am. J. Physiol. Lung Cell Mol. Physiol., 287, L1017, 10.1152/ajplung.00072.2004 Melian, 2002, Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension, Drugs, 62, 107, 10.2165/00003495-200262010-00005 Akiba, 1986, Vasodilator actions of TRK-100, a new prostaglandin I2 analogue, Br. J. Pharmacol., 89, 703, 10.1111/j.1476-5381.1986.tb11174.x Fujita, 2001, PGl2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency, Prostaglandins Leukotrienes Essent. Fatty Acids, 65, 223, 10.1054/plef.2001.0315